OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: APRINOIA Therapeutics Inc

2 Projects | 1 Researchers | $4,357,900 Invested

2023

APRINOIA Therapeutics Inc

Lili Zhang, Ph.D.

A Phase 3, Open-Label, Multicenter, Cross-sectional Study of the Diagnostic Efficacy and Safety of [18F]APN-1607 (APN-1607) Positron Emission Tomography in Patients with Progressive Supranuclear Palsy (PSP) Compared to Age-Matched Controls

  • Funding Amount: $3,558,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Tau
  • Status: Active

2023

APRINOIA Therapeutics Inc

Lili Zhang, Ph.D.

Developing PROTAC tau degrader to reduce pathological tau accumulation for the treatment of Alzheimer’s disease and related tauopathies

  • Funding Amount: $799,900
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Closed